Entresto
E584152
Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Entresto canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6311255 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Entresto Context triple: [Novartis, notableDrug, Entresto]
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
E.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Entresto Target entity description: Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
E.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
brand name medication
ⓘ
pharmaceutical drug ⓘ |
| actsOn | renin-angiotensin-aldosterone system ⓘ |
| ATCCode | C09DX04 ⓘ |
| blackBoxWarning | fetal toxicity ⓘ |
| containsSubstanceRole |
angiotensin II receptor blocker
ⓘ
neprilysin inhibitor ⓘ |
| contraindication |
concomitant use with ACE inhibitors
ⓘ
history of angioedema related to ACE inhibitor or ARB therapy ⓘ pregnancy ⓘ |
| developer | Novartis NERFINISHED ⓘ |
| drugClass |
ARNI
ⓘ
angiotensin receptor neprilysin inhibitor ⓘ |
| effect |
reduces cardiovascular mortality in heart failure patients
ⓘ
reduces hospitalization for heart failure ⓘ |
| hasActiveIngredient |
sacubitril
ⓘ
valsartan ⓘ |
| hasComponentOfFixedDoseCombination |
sacubitril
ⓘ
valsartan ⓘ |
| hasDosageForm | film-coated tablet ⓘ |
| indication |
chronic heart failure
ⓘ
heart failure with reduced ejection fraction ⓘ reduction of risk of cardiovascular death and hospitalization for heart failure ⓘ |
| legalStatusEU | prescription only medicine ⓘ |
| legalStatusUS | Rx-only ⓘ |
| marketingAuthorizationHolder | Novartis NERFINISHED ⓘ |
| mechanismOfAction |
blocks angiotensin II type 1 receptors
ⓘ
inhibits neprilysin to increase natriuretic peptides ⓘ |
| pregnancyCategory | contraindicated in pregnancy ⓘ |
| prescriptionStatus | prescription only ⓘ |
| regulatoryStatus |
EMA approved
ⓘ
FDA approved ⓘ |
| requiresWashoutPeriodWith | ACE inhibitors ⓘ |
| routeOfAdministration | oral ⓘ |
| sideEffect |
cough
ⓘ
dizziness ⓘ hyperkalemia ⓘ hypotension ⓘ renal impairment ⓘ |
| targetPopulation | adult patients with chronic heart failure ⓘ |
| therapeuticArea |
cardiology
ⓘ
heart failure management ⓘ |
| warning |
impaired renal function
ⓘ
risk of angioedema ⓘ risk of hyperkalemia ⓘ risk of hypotension ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Entresto Description of subject: Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.